S&P 500   4,551.68
DOW   35,490.69
QQQ   380.00
S&P 500   4,551.68
DOW   35,490.69
QQQ   380.00
S&P 500   4,551.68
DOW   35,490.69
QQQ   380.00
S&P 500   4,551.68
DOW   35,490.69
QQQ   380.00

Neurocrine Biosciences Price Target, Predictions & Analyst Ratings

-0.58 (-0.57 %)
(As of 10/27/2021 04:00 PM ET)
Today's Range
50-Day Range
52-Week Range
338,410 shs
Average Volume
850,170 shs
Market Capitalization
$9.57 billion
P/E Ratio
Dividend Yield

Neurocrine Biosciences (NASDAQ:NBIX) Price Target and Consensus Rating

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Analyst Rating Consensus

Based on 15 Analyst Ratings

Analyst Price Target Consensus

17.98% Upside

High PT$163.00
Average PT$119.46
Low PT$90.00
10/28/20 to 10/28/21
1 Month Ago
9/28/20 to 9/28/21
3 Months Ago
7/30/20 to 7/30/21
1 Year Ago
10/29/19 to 10/28/20
Consensus Rating
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
8 Buy rating(s)
9 Buy rating(s)
11 Buy rating(s)
12 Buy rating(s)
7 Hold rating(s)
7 Hold rating(s)
6 Hold rating(s)
8 Hold rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$119.46$119.31$123.47$137.39
Price Target Upside17.98% Upside26.65% Upside25.96% Upside13.58% Upside
Get Neurocrine Biosciences Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for NBIX and its competitors with MarketBeat's FREE daily newsletter.

Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

Average Share Price and Price Target by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Neurocrine Biosciences (NASDAQ:NBIX) vs. Its Competitors

TypeNeurocrine BiosciencesMedical CompaniesS&P 500
Consensus Rating Score
Consensus RatingBuyBuyBuy
Price Target Upside17.98% Upside149.79% Upside8.54% Upside
News Sentiment RatingPositive News
Neutral News
Neutral News
Community Rating
Outperform Votes
Underperform Votes
Avg. Outperform Votes
Avg. Underperform Votes
Avg. Outperform Votes
Avg. Underperform Votes

Neurocrine Biosciences (NASDAQ:NBIX) Analyst Ratings History

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
10/18/2021SVB Leerink
M. Goodman
Reiterated RatingMarket Perform
10/14/2021Morgan Stanley
DowngradeOverweight ➝ Equal Weight$110.00 ➝ $112.00+8.06%
9/30/2021HC Wainwright
Andrew Fein
Reiterated RatingBuy
9/22/2021Needham & Company LLC
Initiated CoverageHold
8/6/2021Canaccord Genuity
DowngradeBuy ➝ Hold$122.00 ➝ $108.00+16.52%
5/18/2021The Goldman Sachs Group
Initiated CoverageNeutral$108.00+11.99%
Lower Price Target$112.00 ➝ $107.00+20.67%
Lower Price Target$145.00 ➝ $140.00+57.92%
UpgradeEqual Weight ➝ Overweight$110.00+20.09%
Lower Price TargetNeutral$119.00 ➝ $116.00+22.76%
3/5/2021Robert W. Baird
Reiterated RatingBuy
2/1/2021Raymond James
Initiated CoverageOutperform$163.00 ➝ $163.00+53.69%
1/26/2021William Blair
Reiterated RatingBuy
12/29/2020Cantor Fitzgerald
Lower Price TargetOverweight$168.00 ➝ $121.00+26.66%
11/10/2020Smith Barney Citigroup
Lower Price Target$149.00 ➝ $138.00+57.03%
11/10/2020Credit Suisse Group
Lower Price TargetNeutral$105.00 ➝ $90.00-2.81%
Initiated CoverageHold
8/4/2020Piper Sandler
David Amsellem
Boost Price TargetOverweight$141.00 ➝ $145.00+17.88%
8/4/2020JPMorgan Chase & Co.
DowngradeOverweight ➝ Neutral$136.00+10.56%
Neena Bitritto-Garg
Boost Price TargetBuy$124.00 ➝ $149.00+15.98%
6/18/2020Royal Bank of Canada
Boost Price TargetOutperform$116.00 ➝ $135.00+13.19%
2/14/2020Stifel Nicolaus
Paul Matteis
Reiterated RatingBuy$127.00+21.76%
12/12/2019Piper Jaffray Companies
Reiterated RatingOverweight$116.00 ➝ $153.00+35.10%
Initiated CoverageOutperform ➝ Outperform$100.00+13.93%
Initiated CoverageNeutral ➝ Neutral$88.00+4.50%
4/11/2019Evercore ISI
Initiated CoverageOutperform
2/6/2019Bank of America
Lower Price TargetBuy$124.00 ➝ $117.00+40.76%
(Data available from 10/28/2016 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Neurocrine Biosciences (NASDAQ:NBIX) Analyst Ratings Frequently Asked Questions

What is Neurocrine Biosciences's consensus rating and price target?

According to the issued ratings of 15 analysts in the last year, the consensus rating for Neurocrine Biosciences stock is Buy based on the current 7 hold ratings and 8 buy ratings for NBIX. The average twelve-month price target for Neurocrine Biosciences is $119.46 with a high price target of $163.00 and a low price target of $90.00. Learn more on NBIX's analyst rating history

Do Wall Street analysts like Neurocrine Biosciences more than its competitors?

Analysts like Neurocrine Biosciences stock less than the stock of other Medical companies. The consensus rating score for Neurocrine Biosciences is 2.53 while the average consensus rating score for medical companies is 2.73. Learn more on how NBIX compares to other companies

Do MarketBeat users like Neurocrine Biosciences more than its competitors?

MarketBeat users like Neurocrine Biosciences stock more than the stock of other Medical companies. 82.75% of MarketBeat users gave Neurocrine Biosciences an outperform vote while medical companies recieve an average of 67.30% outperform votes by MarketBeat users.

Is Neurocrine Biosciences being downgraded by Wall Street analysts?

Over the previous 90 days, Neurocrine Biosciences's stock had 2 downgrades by analysts.

Does Neurocrine Biosciences's stock price have much upside?

According to analysts, Neurocrine Biosciences's stock has a predicted upside of 25.61% based on their 12-month price targets.

What analysts cover Neurocrine Biosciences?

Neurocrine Biosciences has been rated by Canaccord Genuity, HC Wainwright, Morgan Stanley, Needham & Company LLC, and SVB Leerink in the past 90 days.

This page was last updated on 10/28/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.